Canopy Cancer Collective

What Canopy Cancer Collective does

Canopy Cancer Collective is a U.S. nonprofit learning health network founded in 2020 that operates under the exempt status of the 1440 Foundation, a private operating foundation co-created by Joanie and Scott Kriens. Its stated mission is to transform outcomes in pancreatic and gastrointestinal cancers through collaborative research and whole-person care. The Collective's primary activity is convening and operating a network of 14 NCI-designated cancer centers — including Johns Hopkins, Mass General, Stanford Medicine, UCLA, UCSF, UT Southwestern, Roswell Park, Moffitt, Mount Sinai, Northwell Health, Fred Hutchinson, UC San Diego, and Ohio State — which collectively organize multidisciplinary care teams (oncologists, surgeons, dietitians, nurse practitioners, supportive care providers, and a patient thriver advisory council) at member institutions.

The Collective does not sell software or charge member fees; its "product" surface consists of the multidisciplinary care model framework itself, annual in-person Learning Sessions (2024 at 1440 Multiversity, 2025 at UT Southwestern), and a growing body of clinical knowledge artifacts, most notably the first-ever U.S. consensus statements on identifying and managing Exocrine Pancreatic Insufficiency (EPI) and PERT in pancreatic oncology, published in 2024 with the Expert Working Group and Polaris Global Health Solutions. The go-to-market is a channel-partner motion in which healthcare systems apply to join the network and Canopy helps them establish interdisciplinary leadership and adopt shared best practices.

Commercially, the organization is funded by sponsorship of its Learning Sessions across Platinum (Health Catalyst, HistoSonics, Ipsen), Gold (AbbVie, Carevive, Natera, Artios Pharma), Silver (xCures, Foundation Medicine, Revolution Medicines, MyCareGorithm, Artidis), and Bronze (Morningside Capital) tiers, plus the underlying support of the 1440 Foundation. Leadership includes Executive Director Dr. Carrie Stricker (formerly Co-founder/CCO of Carevive and 17 years at Penn Abramson Cancer Center), Chief Medical Advisor Dr. Michael Pishvaian (Johns Hopkins), Cancer Research and Collaboration Lead Willy Hoos (also CCO of xCures), Director of Data Management Jeffrey Barrett, and Co-creators Joanie and Scott Kriens. The Collective's most recent strategic move is a data-platform buildout with Health Catalyst to formalize a shared pancreas and GI oncology data model across its member centers.

Name

Canopy Cancer Collective

Legal name

Canopy Cancer Collective, LLC

Website

https://canopycancer.org

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

11–50 employees

Short description

Canopy Cancer Collective is a U.S. nonprofit learning health network of 14 NCI-designated cancer centers that develops and disseminates collaborative, multidisciplinary best practices to improve outcomes for pancreatic and gastrointestinal cancer patients.

Ownership category

akta.pro rank

Product category

Cancer Care Collaborative Network

NAICS

Professional Organizations (81392), Business Associations (813910)

SIC

Services-Membership Organizations (8600)

akta.pro primary industry

Healthcare & Clinical Professional Development (CME/CE) (EDAGANAJ)

akta.pro secondary industries

Association & Society Conference Management (Nonprofit, Professional Bodies) (THAHACAA), Hospital-Integrated Cancer Centers (Acute Oncology Programs) (HLAFAAAM)

Keywords

• Learning health network
• Pancreatic cancer care
• Oncology collaborative care
• Multidisciplinary cancer care
• Cancer care consortium

Headquarters

HQ city

Saratoga

HQ country

United States

HQ region

North America

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Nonprofit membership/participation model: Canopy Cancer Collective is a nonprofit organization that helps organize multidisciplinary clinics at leading healthcare facilities. The organization does not pay for nor reimburse costs of specific treatments. While specific donors or sponsors might fund parts of the work Canopy delivers, their role is to catalyze and nurture programs at member facilities. Healthcare systems determine which insurance programs are applicable to the care provided.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Canopy Cancer Collective runs a nonprofit learning health network that partners with 14 leading NCI-designated cancer centers to develop, share, and scale best practices for pancreatic and gastrointestinal cancer care. Member institutions apply to join and gain access to shared data, consensus care pathways, interdisciplinary expertise, and annual Learning Sessions; the organization also publishes the first U.S. consensus statements on EPI/PERT management and produces patient and provider educational resources.

Product overview

Canopy Cancer Collective is a nonprofit learning health network focused on transforming outcomes in pancreas and gastrointestinal cancers. The organization does not offer a traditional software product but rather provides programs and services including: multidisciplinary care collectives connecting leading NCI-designated cancer centers, annual learning sessions for knowledge sharing among oncology professionals, and evidence-based clinical resources such as EPI/PERT consensus statements and patient/provider educational materials. The core offering is the collaborative care model that enables participating healthcare systems to deliver comprehensive, coordinated cancer care through shared best practices and data.

Differentiator

Problem solved

Functional benefit

Products and services

• Multidisciplinary Cancer Care Collectives A collaborative care model connecting top medical care providers, cancer researchers, and wellness specialists across 14 leading NCI-designated cancer centers to deliver comprehensive, coordinated, whole-person care for pancreatic and gastrointestinal cancer patients. Available to healthcare systems that apply and are accepted as members.
• Annual Learning Sessions Annual in-person learning sessions bringing together world leaders in pancreatic and gastrointestinal oncology to share best practices, accelerate innovation in cancer treatment, care delivery, and outcomes across the Canopy network.
• EPI/PERT White Paper and Consensus Statements From Overlooked to Essential: Transforming Pancreatic Cancer Care with EPI Management — the first U.S. consensus statements on identifying and managing Exocrine Pancreatic Insufficiency in pancreatic oncology practice. Published for oncology clinicians, allied health professionals, and healthcare systems.
• Patient Guide to Exocrine Pancreatic Insufficiency (EPI) Patient Guide to Exocrine Pancreatic Insufficiency (EPI) in Pancreatic Cancer — explains symptoms, treatment, and daily management for EPI and Pancreatic Enzyme Replacement Therapy (PERT). Designed for pancreatic cancer patients and caregivers.
• Healthcare Provider EPI Management Summary Tool A Summary For Healthcare Teams: the first U.S. consensus statements on identifying and managing EPI in pancreatic oncology — an executive summary tool for healthcare teams to apply Canopy's consensus in clinical practice.
• Supportive Care and Nutrition Pathways Evidence-based clinical pathways for supportive care and nutrition in pancreatic cancer treatment, including recommended assessments, referral algorithms, and integration of patient-reported outcomes — used by member cancer centers to standardize supportive oncology services.

Quantifiable outcome

• Network-wide goal set to screen every patient seen across 14 NCI-designated cancer centers for exocrine pancreatic insufficiency (EPI) in 2023
• +1 more outcomes

Named customers13 records

Segments2 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

28 partnerships are on record, tiered platinum, gold, silver, core and minor.

• Health CatalystplatinumGTM or Marketing Partner · 26 October 2025Platinum sponsor of the 2025 Learning Session. Leading provider of data and analytics technology and services to healthcare organizations. Contributes to building the pancreas and GI oncology data model.
• Artios PharmagoldGTM or Marketing Partner · 26 October 2025Gold sponsor of the 2025 Learning Session. Pioneering approaches in DNA damage response (DDR) field with ATR inhibitor ART0380. Actively seeking partnerships with cooperative groups like Canopy.
• Revolution MedicinessilverGTM or Marketing Partner · 26 October 2025Silver sponsor. Focused on discovering, developing and delivering innovative targeted therapies for patients with RAS-addicted cancers. Pioneering RAS(ON) inhibitors.
• Foundation MedicinesilverGTM or Marketing Partner · 26 October 2025Silver sponsor. Provides multi-modal precision diagnostic solutions transforming cancer care from pre-diagnosis to ongoing management and monitoring. Partnering to accelerate development of personalized therapies.
• ArtidissilverGTM or Marketing Partner · 26 October 2025Silver sponsor. Clinical stage health technology company focused on tissue analysis and therapy optimization combining nanotechnology platform with holistic data solutions for solid tumors.
• Pancreatic Cancer Action Network (PanCAN)coreStrategic or Co-development Partner · 26 October 2025Key strategic partner in the learning network. Partnership focuses on implementing molecular navigation to drive personalized care and innovative science. Contributes patient advocacy and clinical trial portfolio expertise.
• Polaris Global Health SolutionscoreStrategic or Co-development Partner · 26 October 2025Collaborative partner in developing the first U.S. consensus statements on exocrine pancreatic insufficiency (EPI) management. Led qualitative research and convened the Expert Working Group.
• HistoSonicsplatinumGTM or Marketing Partner · 6 November 2024Platinum sponsor of the 2024 Learning Session. HistoSonics is developing a non-invasive sonic beam therapy platform and procedure to liquify and destroy targeted tissue including tumors at sub-cellular levels. Conducted a lunch breakout session at the conference.
• IpsenplatinumGTM or Marketing Partner · 6 November 2024Platinum sponsor of the 2024 Learning Session. Global biopharmaceutical company dedicated to developing medicines in oncology, rare disease, and neuroscience. Hosted a breakfast session with study investigators at the 2025 Learning Session.
• AbbViegoldGTM or Marketing Partner · 6 November 2024Gold sponsor of the 2024 Learning Session. AbbVie's mission is to discover and deliver innovative medicines and solutions that address complex health issues and enhance people's lives.
• CarevivegoldGTM or Marketing Partner · 6 November 2024Gold sponsor of the 2024 Learning Session. Oncology-focused health technology company centered on understanding and improving the experience of patients with cancer. Co-founded by Canopy's Executive Director Dr. Carrie Stricker.
• NateragoldGTM or Marketing Partner · 6 November 2024Gold sponsor of the 2024 Learning Session. Global leader in cell-free DNA testing dedicated to advancing precision oncology. Signatera test is used for detecting molecular residual disease and monitoring recurrence.
• MyCareGorithmsilverGTM or Marketing Partner · 6 November 2024Silver sponsor developing tools to transform the consultation encounter between a cancer patient and cancer specialist with a personalized educational experience.
• xCuressilverGTM or Marketing Partner · 6 November 2024Silver sponsor. AI-assisted platform that can automatically retrieve medical records from anywhere in the US within 15 minutes and extract vital data. Canopy's Willy Hoos serves as Chief Commercial Officer.
• Fred Hutchinson Cancer Research CentercoreStrategic or Co-development PartnerMember of Canopy's pancreatic cancer learning network. Fred Hutch participates in shared data, best practices, and quality improvement initiatives. Contributed to supportive care and intake/navigation program highlights at the 2024 Learning Session.
• Johns Hopkins Oncology CentercoreStrategic or Co-development PartnerMajor member contributing leadership to the collective. Dr. Mike Pishvaian serves as Chief Medical Advisor. Contributes expertise in GI oncology, developmental therapeutics, clinical research programs, and genomics testing.
• Mass General Cancer CentercoreStrategic or Co-development PartnerMember institution bringing expertise in gastrointestinal radiation oncology. Contributes to learning network discussions on improving radiation treatment approaches for pancreatic cancer.
• Moffitt Cancer CentercoreStrategic or Co-development PartnerMember of the pancreatic cancer learning network participating in collaborative care improvement initiatives and best practices sharing.
• Mount Sinai Cancer CentercoreStrategic or Co-development PartnerMember contributing expertise in GI medical oncology. Contributes to germline genetic testing best practices and research initiatives.
• Northwell Health Cancer InstitutecoreStrategic or Co-development PartnerCore member and host institution affiliated with Cold Spring Harbor Cancer Center. An application for combined NCI designation is in progress. Contributes leadership including Dr. Matt Weiss, Professor of Surgery and Oncology.
• Stanford Medicine Cancer InstitutecoreStrategic or Co-development PartnerMember contributing expertise in comprehensive patient care including social work, nutrition education, and supportive care. Dr. George Fisher provides leadership on patient-centric care approaches.
• The Ohio State University Cancer CentercoreStrategic or Co-development PartnerMember of the pancreatic cancer learning network participating in multidisciplinary care improvement initiatives.
• Roswell Park Cancer CentercoreStrategic or Co-development PartnerMember contributing expertise in palliative and supportive care. Dr. Desi Carozza represents Roswell Park at learning sessions focusing on value proposition redesign.
• UCLA HealthcoreStrategic or Co-development PartnerMember contributing advanced practice dietitians and expertise in nutrition pathways. Contributes to patient-reported outcomes (PROs) integration and supportive care program development.
• UC San Diego Cancer CentercoreStrategic or Co-development PartnerMember contributing pancreatic cancer nurse practitioner expertise and strategies for improving trial enrollment. Active in ctDNA analysis and timely treatment implementation.
• UCSF HealthcoreStrategic or Co-development PartnerMember contributing expertise in germline genetic testing best practices. Participates in genomics testing initiatives and collaborative research.
• UT Southwestern Cancer CentercoreStrategic or Co-development PartnerHost of the 2025 Learning Session in Dallas, Texas. Key member contributing co-directors for pancreatic cancer program. Leads strategic initiatives including ctDNA roadmap development and surgical interventions improvement.
• Let's Win Pancreatic CancerminorStrategic or Co-development PartnerPatient advocacy partner contributing to value proposition discussions and patient-centered care initiatives. Cindy Price Gavin serves as CEO and Co-Founder.

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Broad incumbents

• ECOG-ACRIN Cancer Research Group: Another NCI-sponsored cooperative group running multi-center oncology trials. Comparable to Canopy as a multi-center oncology collaboration involving leading academic institutions.
• National Comprehensive Cancer Network (NCCN): The pre-eminent alliance of 31 leading U.S. academic cancer centers that publishes the oncology guidelines used across the field. Comparable to Canopy as a multi-center collaborative authority that shapes clinical standards, though broader in scope (all oncology, all member guidelines).
• SWOG Cancer Research Network: An NCI-sponsored cancer clinical trials cooperative group that engages many of the same academic centers as Canopy. Comparable as a multi-institution oncology research network, though anchored on clinical trial execution rather than care delivery learning networks.
• ASCO CancerLinQ: ASCO's learning health network that aggregates real-world oncology data across practices. Comparable to Canopy's data-driven learning network model and consensus-driven quality improvement, though broader in scope and oncology-wide.

Direct peers

• Lustgarten Foundation: A large pancreatic cancer research foundation supporting multi-institution research collaborations. Directly comparable to Canopy in mission focus on pancreatic cancer and funding of cross-center research.
• Pancreatic Cancer Action Network (PanCAN): The leading U.S. nonprofit advocacy and research organization for pancreatic cancer. Directly comparable to Canopy because it works in the same disease, engages overlapping NCI-designated centers, and is now a strategic partner of Canopy's learning network.
• Let's Win Pancreatic Cancer: A patient-driven pancreatic cancer nonprofit focused on education and clinical trial navigation. Already a strategic partner of Canopy, it is the closest peer in the patient-education and pancreatic-cancer-mission space.
• ORIEN (Oncology Research Information Exchange Network): A learning health network of leading U.S. cancer centers that share longitudinal clinical and molecular data. Mirrors Canopy's model of using shared data and learning across NCI centers but operates across all cancer types rather than pancreatic focus.

Emerging players

• Tapestry Networks: A firm that convenes leadership networks across healthcare and oncology. Comparable to Canopy in its network-based model of accelerating consensus among clinical leaders, though private-sector and disease-agnostic.

Others

• Health Catalyst: A leading healthcare data and analytics company that is now a Platinum sponsor of Canopy's 2025 Learning Session and is collaborating on Canopy's pancreas/GI oncology data model. Comparable as an adjacent enabling technology partner for learning health networks.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/CanopyCancer
• LinkedInlinkedin.com/company/canopycancer

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Canopy Cancer Collective